Skip to main content

Advertisement

SpringerLink
Log in

Effects of high dose of zoledronic acid on superficial vascular network of membranous bone sites: an intravital study on rat calvarium

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Summary

We evaluated the impact of high dose of zoledronic acid on the superficial vascular network parameters of a membranous bone site. During a 5-day follow-up, significant reduction of the vascular density is observed only in the treated group.

Introduction

The superficial vascularization is of great importance in membranous bone-healing process. A new rat calvarium intravital model was developed to study the short-term effect of a single high dose of zoledronic acid infusion on the superficial vascularization.

Methods

Optical bone chambers were implanted in the bone tissue surface of Sprague-Dawley rats' calvarium. Nine rats were injected i.v. with 400 µg/kg of zoledronic acid (Z group), and nine rats were injected with vehicle (PSS group). A 5-day follow-up of the vascular network was made by the use of pictures analysis method.

Results

The vascular density significantly decreases only in Z group but there was no significant difference between groups at individual time points. The total length of the vascular network decreases significantly in Z group only (p = 0.003) with a significant higher decrease at D3 (p = 0.04) and D5 (p = 0.02) compared with control. The vascular density related to the smaller vessels (width, 5–10 µm) decreases significantly between T0 and D5 in Z group only (p = 0.002).

Conclusions

With the help of an original intravital animal model a significant modifications on the total length of the vascular network and the vascular density of small vessels are highlighted on a membranous bone site.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Brown JE, Ellis SP, Lester JE, Gutcher S, Khanna T, Purohit OP et al (2007) Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid. Clin Cancer Res 13:5406–5410

    Article  CAS  PubMed  Google Scholar 

  2. Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L et al (2008) Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19:420–432

    Article  CAS  PubMed  Google Scholar 

  3. Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y et al (2005) Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med 353:898–908

    Article  CAS  PubMed  Google Scholar 

  4. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822

    Article  CAS  PubMed  Google Scholar 

  5. Green JR (2003) Antitumor effects of bisphosphonates. Cancer 97:840–847

    Article  PubMed  Google Scholar 

  6. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C et al (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679–691

    Article  CAS  PubMed  Google Scholar 

  7. Daubine F, Le Gall C, Gasser J, Green J, Clezardin P (2007) Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 99:322–330

    Article  CAS  PubMed  Google Scholar 

  8. Stresing V, Daubine F, Benzaid I, Monkkonen H, Clezardin P (2007) Bisphosphonates in cancer therapy. Cancer Lett 257:16–35

    Article  CAS  PubMed  Google Scholar 

  9. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM et al (2002) Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302:1055–1061

    Article  CAS  PubMed  Google Scholar 

  10. Wood J, Schnell C, Green JR (2000) Zoledronic acid, a potent inhibitor of bone resorption, inhibits proliferation and induces apoptosis in human endothelial cells in vitro and is antiangiogenic in a murine growth factor implant model. Proc Am Soc Clin Oncol 19:664

    Google Scholar 

  11. Streeten EA, Brandi ML (1990) Biology of bone endothelial cells. Bone Miner 10:85–94

    Article  CAS  PubMed  Google Scholar 

  12. Shenker NG, Jawad AS (2007) Bisphosphonates and osteonecrosis of the jaw. Rheumatology (Oxford) 46:1049–1051

    Article  CAS  Google Scholar 

  13. Ruggiero SL, Drew SJ (2007) Osteonecrosis of the jaws and bisphosphonate therapy. J Dent Res 86:1013–1021

    Article  CAS  PubMed  Google Scholar 

  14. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527–534

    Article  PubMed  Google Scholar 

  15. Somerman MJ (2006) Bisphosphonates: saccrificing the jaw to save the skeleton? BoneKEy-Osteovision 3:12–18

    Google Scholar 

  16. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D et al (2007) Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479–1491

    Article  PubMed  Google Scholar 

  17. Penel G, Delfosse C, Descamps M, Leroy G (2005) Composition of bone and apatitic biomaterials as revealed by intravital Raman microspectroscopy. Bone 36:893–901

    Article  CAS  PubMed  Google Scholar 

  18. Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M et al (2002) Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62:6538–6544

    CAS  PubMed  Google Scholar 

  19. Gasser JA, Ingold P, Venturiere A, Shen V, Green JR (2008) Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat. J Bone Miner Res 23:544–551

    Article  CAS  PubMed  Google Scholar 

  20. Desmons S, Heger M, Delfosse C, Falgayrac G, Sarrazin T, Delattre C et al (2009) A preliminary investigation into the effects of X-rays radiation on superficial cranial vascularization. Calcif Tissue Int 84:379–387

    Article  CAS  PubMed  Google Scholar 

  21. Thompson HJ, McGinley JN, Knott KK, Spoelstra NS, Wolfe P (2002) Vascular density profile of rat mammary carcinomas induced by 1-methyl-1-nitrosourea: implications for the investigation of angiogenesis. Carcinogenesis 23:847–854

    Article  CAS  PubMed  Google Scholar 

  22. Verbeke G, Molenberghs G (2000) Linear Mixed Models for longitudinal data. Springer Verlag, New York

    Google Scholar 

  23. Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S et al (2002) Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastasis. J Clin Pharmacol 42:1228–1236

    Article  CAS  PubMed  Google Scholar 

  24. Santini D, Vincenzi B, Dicuonzo G, Avvisati G, Massacesi C, Battistoni F et al (2003) Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 9:2893–2897

    CAS  PubMed  Google Scholar 

  25. Santini D, Vincenzi B, Tonini G, Scarpa S, Baldi A (2003) Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 9:3215; author reply 3216

    Google Scholar 

  26. Santini D, Vincenzi B, Galluzzo S, Battistoni F, Rocci L, Venditti O et al (2007) Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 13:4482–4486

    Article  CAS  PubMed  Google Scholar 

  27. Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E (2008) Effect of zoledronic acid on serum angiogenic factors in patients with one metastases. Med Oncol 25:346–349

    Article  CAS  PubMed  Google Scholar 

  28. Colleran PN, Wilkerson MK, Bloomfield SA, Suva LJ, Turner RT, Delp MD (2000) Alterations in skeletal perfusion with simulated microgravity: a possible mechanism for bone remodeling. J Appl Physiol 89:1046–1054

    CAS  PubMed  Google Scholar 

  29. Laroche M (2002) Intraosseous circulation from physiology to disease. Joint Bone Spine 69:262–269

    Article  PubMed  Google Scholar 

  30. Hansen T, Kunkel M, Weber A, James Kirkpatrick C (2006) Osteonecrosis of the jaws in patients treated with bisphosphonates—histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 35:155–160

    Article  PubMed  Google Scholar 

  31. Hansen T, Kunkel M, Springer E, Walter C, Weber A, Siegel E et al (2007) Actinomycosis of the jaws—histopathological study of 45 patients shows significant involvement in bisphosphonate-associated osteonecrosis and infected osteoradionecrosis. Virchows Arch 451:1009–1017

    Article  PubMed  Google Scholar 

  32. Kapitola J, Zak J (1998) Effect of pamidronate on bone blood flow in oophorectomized rats. Physiol Res 47:237–240

    CAS  PubMed  Google Scholar 

  33. Kapitola J, Zak J, Lacinova Z, Justova V (2000) Effect of growth hormone and pamidronate on bone blood flow, bone mineral and IGF-I levels in the rat. Physiol Res 49(Suppl 1):S101–S106

    CAS  PubMed  Google Scholar 

  34. Selby PL, Davie MW, Ralston SH, Stone MD (2002) Guidelines on the management of Paget's disease of bone. Bone 31:366–373

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was realised with a research grant from the French Society of Rheumatology. Zoledronic acid was kindly provided by Novartis Pharma AG, Basel, Switzerland.

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of Rheumatology, Hôpital Roger Salengro, University Lille Nord de France, CHRU Lille, 59037, Lille cedex, France

    M. H. Vieillard, J. Paccou, B. Cortet & E. Biver

  2. CERIM, University Lille Nord de France, Lille, France

    J. Salleron

  3. EA 4032, IFR 114, School of Dentistry, University Lille Nord de France IMPRT, Place de Verdun, 59000, Lille, France

    G. Falgayrac & G. Penel

Authors
  1. M. H. Vieillard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Paccou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Cortet
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. Biver
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Salleron
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Falgayrac
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G. Penel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. Penel.

Additional information

Julien Paccou and Marie H. Vieillard contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vieillard, M.H., Paccou, J., Cortet, B. et al. Effects of high dose of zoledronic acid on superficial vascular network of membranous bone sites: an intravital study on rat calvarium. Osteoporos Int 21, 1919–1925 (2010). https://doi.org/10.1007/s00198-009-1146-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-009-1146-0

Keywords

Search

Navigation